2. Gómez Rufo D., García Sánchez E., García Sánchez J.E., García Moro M. Implicaciones clínicas de las especies del género Mycoplasma (Clinical implications of the genus Mycoplasma). Rev. Esp. Quimioter. 2021; 34(3): 169–84. DOI: 10.37201/req/014.2021

3. Спичак Т.В. Респираторная микоплазменная инфекция у детей: насколько мы продвинулись в решении проблем? Педиатрия. Журнал им. Г. Н. Сперанского. 2015; 6(94): 128–33.

Spichak T.V. (Respiratory mycoplasma infection in children: how far have we come in solving problems?) Pediatrics. Journal named after G. N. Speransky. 2015; 6(94): 128–33. (In Russ.).

4. Garnier J.M., Noël G., Retornaz K., Blanc P., Minodier P. Extrapulmonary infections due to Mycoplasma pneumoniae. Arch Pediatr. 2005; 12(1): S2–6. DOI: 10.1016/s0929-693x(05)80002-8.

5. Wang X., Lin X. Analysis of Clinical Related Factors of Severe Mycoplasma pneumoniae Pneumonia in Children Based on Imaging Diagnosis. Comput. Math. Methods Med. 2022; 2022: 4852131. DOI: 10.1155/2022/4852131

6. Kumar S., Roy R.D., Sethi G.R., Saigal S.R. Mycoplasma pneumoniae infection and asthma in children. Trop. Doct. 2019; 49(2): 117–9. DOI: 10.1177/0049475518816591

7. Liu X., Wang Y., Chen C., Liu K. Mycoplasma pneumoniae infection and risk of childhood asthma: A systematic review and meta-analysis. Microb. Pathog. 2021; 155: 104893. DOI: 10.1016/j.micpath.2021.104893

8. Meyer Sauteur P.M., Chalker V.J., Berger C., Nir-Paz R., Beeton M.L.; ESGMAC and the ESGMAC–MyCOVID study group. Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? Lancet Microbe 2022; 3(12): e897. DOI: 10.1016/S2666-5247(22)00190-2

9. BIOFIRE Diagnostics, 2023. Respiratory Pathogen Trends. https://syndromictrends.com/

10. Choubey A., Sagar D., Cawley P., Miller K. Retrospective review analysis of COVID-19 patients co-infected with Mycoplasma pneumoniae. Lung Indiа 2021; 38(Suppl.): S22–S26. DOI: 10.4103/lungindia.lungindia_607_20

11. Oliva A., Siccardi G., Migliarini A., Cancelli F., Carnevalini M., D'Andria M. et al. Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature. Infection 2020; 48(6): 871–7. DOI: 10.1007/s15010-020-01483-8

12. Cai X., Jiang H., Zhang S., Xia S., Du W., Ma Y. et al. Clinical manifestations and pathogen characteristics in children admitted for suspected COVID-19. Front. Med. 2020; 14(6): 776–85. DOI: 10.1007/s11684-020-0820-7

13. Amin D., McKitish K., Shah P.S. Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients. J. Med. Virol. 2021; 93(2): 1180–3. DOI: 10.1002/jmv.26467

14. Medjo B., Atanaskovic-Markovic M., Radic S., Nikolic D., Lukac M., Djukic S. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Ital. J. Pediatr. 2014; 40: 104. DOI: 10.1186/s13052-014-0104-4

15. Kumar S., Garg I.B., Sethi G.R., Kumar S., Saigal S.R. Detection of immunoglobulin M and immunoglobulin G antibodies to Mycoplasma pneumoniae in children with community-acquired lower respiratory tract infections. Indian J. Pathol. Microbiol. 2018; 61(2): 214–8. DOI: 10.4103/IJPM.IJPM_21_17

16. Meyer Sauteur P.M., Beeton M.L., Uldum S.A., Bossuyt N., Vermeulen M., Loens K. et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022; 27(19): 2100746. DOI: 10.2807/1560-7917.ES.2022.27.19.2100746

17. Jiang Z., Li S., Zhu C., Zhou R., Leung P.H.M. Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development. Pathogens 2021; 10(2): 119. DOI: 10.3390/pathogens10020119

18. Gavitt T.D., Mara A.B., Goodridge M.L., Ozyck R.G., Reinhardt E., Miller J.M. et al. B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs. NPJ Vaccines 2022; 7(1): 130. DOI: 10.1038/s41541-022-00556-z

19. Beeton M.L., Zhang X.S., Uldum S.A., Bébéar C., Dumke R., Gullsby K. et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill. 2020; 25(2): 1900112. DOI: 10.2807/1560-7917.ES.2020.25.2.1900112

20. Gordon O., Oster Y., Michael-Gayego A., Marans R.S., Averbuch D., Engelhard D. et al. The Clinical Presentation of Pediatric Mycoplasma pneumoniae Infections-A Single Center Cohort. Pediatr. Infect. Dis. J. 2019; 38(7): 698–705. DOI: 10.1097/INF.0000000000002291

21. Царькова С.А., Костенко Д.Е., Онищенко О.А. Характеристика микоплазменной пневмонии у детей и анализ качества антимикробной терапии. Вестник Уральского государственного медицинского университета 2019; (3–4): 108–13.

Tsarkova S.A., Kostenko D.E., Onishchenko O.A. (Characteristic of Mycoplasma pneumonia in children and quality analysis of antimicrobial therapy). Bulletin of the Ural State Medical University 2019; (3–4): 108–13. (In Russ.).

22. Almasri M., Diza E., Papa A., Eboriadou M., Souliou E. Mycoplasma pneumoniae respiratory tract infections among Greek children. Hippokratia 2011; 15(2): 147–52.

23. Jiang T.T., Sun L., Wang T.Y., Qi H., Tang H., Wang Y.C. et al. The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Front Cell Infect. Microbiol. 2023; 13: 1181402. DOI: 10.3389/fcimb.2023.1181402

24. Wei W., Wang X.F., Liu J.P., Shen K.L., Ma R., Cui Z.Z. et al. (Status of antibiotic use in hospitalized children with community-acquired pneumonia in multiple regions of China). Zhongguo Dang Dai Er Ke Za Zhi 2019; 21(1): 11–7. Chinese. DOI: 10.7499/j.issn.1008-8830.2019.01.003